Safety & Efficacy of Nuberol Forte® in Pain Management

Phase

N/A

Condition

Essential Tremor

Musculoskeletal Diseases

Arthritis And Arthritic Pain

Treatment

N/A

Clinical Study ID

NCT04765787

TSCL_NFORT-EFFECT_001

Ages 18-70
All Genders

Study Summary

The global prevalence of Musculoskeletal disorders (MSD) ranges from 14% to as high as 42%. In addition WHO also estimates that 40% of people over the age of 60 years suffer from MSD and about 80% of the people have had low back pain at some point in their life. In Pakistan, to estimate the prevalence of MSD, there is no data available based on the local population. Locally, studies were conducted on the specific subject pools mainly considering the work related musculoskeletal disorders and backache. However, no real data is available for the symptomatic management of painful musculoskeletal disorders in multiple settings to calculate more generalizable results. So this study is planned and if we found good results then it will help physicians to prescribe the above said medicine to all such cases.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Patient with a clinical history of painful musculoskeletal disorder from last 1 year
Patient aged ≥18 and ≤70 years inclusive of either sex
Patient with ability to understand and sign written informed consent form.

Exclusion

Exclusion Criteria:

Known hypersensitivity to Nuberol Forte product, the metabolites, or formulationexcipients.
Patients with Glaucoma, prostatic hypertrophy or obstruction at the bladder neck,myasthenia gravis, oesophageal spasm and pyloric or duodenal obstruction.
Treated with Nuberol Forte to evaluate safety as per approved prescribing informationfor Nuberol Forte in Pakistan.
Pregnant (assesed on LMP) or breast feeding women (assessed on interview).

Study Design

November 25, 2020

August 01, 2021

Study Description

The management of musculoskeletal pain is complex therefore plethora of treatment options are available include non-pharmacological treatments , complementary therapies, and pharmacological interventions. In order to provide optimal care to patients with musculoskeletal pain and ensure the efficient use of healthcare resources, a comprehensive overview of the available evidence for the most effective treatment options for musculoskeletal pain presentations is essential. In this context, an observational study is planned on the efficacy and safety of analgesic combination (i.e Nuberol Forte®). Nuberol Forte® is a combination of muscle relaxant (Orphanedrine) and an analgesic/antipyretic (Paracetamol/Acetaminophen). There are clear indications that the combination of Orphenadrine with Paracetamol may give increased antinociceptive activity and duration of action over and above the use of Orphenadrine or Paracetamol alone.

Connect with a study center

Liaquat National Hospital
Karachi, Sindh
Pakistan
Site Not Available
Medicare Hospital
Karachi, Sindh
Pakistan
Site Not Available
Patel Hospital
Karachi, Sindh
Pakistan
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.